Liesenfeld A, Havemann K, Gropp C, Seifert W, Thomas C, Drings P, Mahnke H G, Westerhausen M, Wellens W, Konrad R M
Onkologie. 1984 Jun;7(3):145-51. doi: 10.1159/000215427.
Between March 1979 und January 1983 122 patients with small-cell carcinoma of the lung were treated with different polychemotherapy regimen. 33 patients received VP-16-213 (etoposid), ifosfamide and vindesine (VPIV). 37 patients were treated with adriamycin, cisplatin and vincristine (APO). A third 3-drug combination, cyclophosphamide, methotrexate and CCNU (CMCC), was given to the remaining 52 patients alternating with the two other regimen. Response rates varied between 61% for the APO regimen and 85% for the VPIV regimen. The median survival was 10 months for patients treated with VPIV or APO and 12 months for patients treated with alternating drug combinations. This difference was not statistically significant. The rate of long-term survivors (longer than 2 years after diagnosis) was 9.9%. Side effects were seen more frequently in the group treated with APO.
1979年3月至1983年1月期间，122例肺小细胞癌患者接受了不同的多药化疗方案治疗。33例患者接受依托泊苷（VP - 16 - 213）、异环磷酰胺和长春地辛（VPIV）治疗。37例患者接受阿霉素、顺铂和长春新碱（APO）治疗。其余52例患者接受第三种三联药物组合，即环磷酰胺、甲氨蝶呤和洛莫司汀（CMCC），并与其他两种方案交替使用。缓解率在APO方案的61%至VPIV方案的85%之间。接受VPIV或APO治疗的患者中位生存期为10个月，接受交替药物组合治疗的患者中位生存期为12个月。这种差异无统计学意义。长期存活者（诊断后超过2年）的比例为9.9%。APO治疗组的副作用出现得更频繁。
